Our Vision, Mission and Core Values

Launched in September 2012, TransCelerate Biopharma Inc. aims to simplify and accelerating the delivery of innovative medicines to patients. With so much progress and so much future opportunity, we have continued to refine our focus. The new statements below reflect our organization’s continued commitment:

Our Vision

To improve the health of people around the world by accelerating and simplifying the research and development of innovative new therapies.

Our Mission

To to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines.

Our Core Values

Quality
Transparency & Openness
Trust & Integrity
Collaboration
Courage

Learn More

For Sites & Training Providers

Resources for Sites and Training Providers, including common Sponsor forms and criteria for GCP  training that are mutually recognized by TransCelerate Member Companies, are available by clicking the button below.

Learn More

Our Events

TransCelerate executives and members present at many industry conferences and meetings all across the globe.  Click on the button below to see a comprehensive list of these events.

Learn More

Latest News

TransCelerate Partners with SCRS on New Site Advocacy Group Initiative

TransCelerate is partnering with the Society for Clinical Research Sites (SCRS) on the launch of its newest initiative, the Site Advocacy Group (SAG). “The SAG is a landmark industry initiative that enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools and […]

TransCelerate Names Annalisa Jenkins as Chair of Its Board of Directors

TransCelerate BioPharma Inc. announced the appointment of Annalisa Jenkins, MBBS, MRCP, former Executive Vice President and Head of Global Research and Development at Merck Serono (biopharma division of Merck KGaA, Darmstadt, Germany), as Chair of its Board of Directors, effective immediately.

Risk-Based Monitoring Update – Volume I

TransCelerate BioPharma Inc. announced the first update to its position paper outlining a methodology for risk-based site monitoring.  The update and related materials can be viewed here.